Epigenetic modulation of CTCs as a novel therapeutic target in oncology

Area of Science:

• Oncology
• Epigenetics
• Cancer Biology

Background:

• Tumor metastasis, driven by circulating tumor cells (CTCs), is a major cause of cancer mortality.
• Epigenetic alterations, alongside genetic mutations, significantly influence gene expression, chromosome stability, and cancer progression.
• Understanding these epigenetic changes is crucial for deciphering tumor cell behavior during metastasis.

Purpose of the Study:

• To provide a comprehensive overview of circulating tumor cell (CTC) biology, including epithelial-mesenchymal transition (EMT), immune surveillance, and colonization.
• To examine the impact of epigenetic modifications within CTCs on their migration, survival, and dissemination during metastasis.
• To discuss the therapeutic implications of targeting epigenetics in CTCs and their potential as biomarkers.

Main Methods:

• This is a narrative review, synthesizing existing research on CTCs and epigenetics.
• Literature search and analysis focusing on epigenetic mechanisms in cancer metastasis.
• Review of studies investigating CTCs as biomarkers and therapeutic targets.

Main Results:

• Epigenetic dysregulation in CTCs plays a pivotal role in carcinogenesis, tumor progression, and metastasis.
• Epigenetic modifications influence key metastatic processes such as CTC migration, survival, and colonization of secondary organs.
• CTCs exhibit potential as valuable biomarkers for early cancer detection, prognosis, and personalized treatment strategies.

Conclusions:

• Epigenetic targeting in CTCs presents a promising strategy for improving cancer patient outcomes.
• Circulating tumor cells (CTCs) hold significant potential as biomarkers for enhanced cancer management.
• Further research into the epigenetic landscape of CTCs can lead to novel therapeutic interventions and improved patient survival rates.